Education
About Us
Working with TipRanks
Follow Us
Todd Davis Insider Profile
4 Followers
Todd Davis, CEO, Director at Ligand Pharma, holds 151.72K shares in Ligand Pharma (Ticker: LGND), holds 29.17K shares in Chromocell Therapeutics Corp (Ticker: CHRO), holds 125.91K shares in Vaxart (Ticker: VXRT).
Profitable Transactions
10 out of 11 Profitable Transactions
Average Return
+0.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Todd Davis holds in companies
Most Profitable Insider Trade
The most profitable trade made by Todd Davis
Todd Davis's Trading History
Ligand Pharma
Mar 06, 2025
CEO, Director
Uninformative Buy
―
$17.42M
BioDelivery
Mar 22, 2022
―
Uninformative Sell
―
$0.00
Vaxart
Aug 08, 2022
Director
Uninformative Buy
―
$59.05K
Chromocell Therapeutics Corp
Feb 23, 2024
Director
Uninformative Buy
140.00K
$63.58K
Palvella Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Todd Davis's performance on stock
You May Also Like
Todd Davis insider profile FAQ
What is the percentage of profitable transactions made by Todd Davis?
The percentage of profitable transactions made by Todd Davis is 91%.
What is the average return per transaction made by Todd Davis?
The average return per transaction made by Todd Davis is 0.50%.
What stocks does Todd Davis hold?
Todd Davis holds: LGND, BDSI, VXRT, CHRO, PVLA stocks.
What was Todd Davis’s latest transaction?
Todd Davis latest transaction was an Uninformative Buy of ―.
What was Todd Davis's most profitable transaction?
Todd Davis’s most profitable transaction was an Informative Buy of LGND stock on September 25, 2023. The return on the trade was 67.80%.
What is Todd Davis's role in Ligand Pharma?
Todd Davis's role in Ligand Pharma is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.